Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02986867 · ClinicalTrials.gov registry record · NA
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
A NA study of Melanoma and Urothelial Carcinoma, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT02986867 is a NA study of Melanoma and Urothelial Carcinoma that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 27 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02986867, a NA study of Melanoma and Urothelial Carcinoma, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR. Tumor core biopsies will be processed and analyzed as described above. Medical records electronic medical records will be used to collect demographic and medical information and imaging studies.
Conditions Studied
Interventions
- RADIATION SAbR Treatment of Lesions
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-06-13 |
| Est. Completion | 2018-03-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02986867
The ClinicalTrials.gov registry entry for NCT02986867 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which SAbR Treatment of Lesions is the first listed.
NCT02986867 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02986867 about?
NCT02986867 is a clinical study titled "SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma". The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR. Tumor core biopsies will be processed and analyzed as described above. Medical records electronic medical records will be used ...
What is the current status of trial NCT02986867?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2017-06-13. Estimated completion is 2018-03-07.
What conditions does trial NCT02986867 study?
This clinical trial studies the following conditions: Melanoma, Urothelial Carcinoma, Cervical Carcinoma in Situ.
What interventions are being tested in trial NCT02986867?
The interventions under investigation include: SAbR Treatment of Lesions (RADIATION).
Who is sponsoring clinical trial NCT02986867?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02986867 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
RECRUITING · NA
-
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
RECRUITING · NA
-
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.